University Hospital of Copenhagen, Rigshospitalet
Welcome,         Profile    Billing    Logout  
 13 Trials 
40 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Daugaard, Gedske
PEACE III, NCT02194842 / 2014-001787-36: Phase III Radium 223 mCRPC-

Active, not recruiting
3
446
Europe, Canada, RoW
Ra223, Enzalutamide
European Organisation for Research and Treatment of Cancer - EORTC, Bayer, Astellas Pharma Europe Ltd., UNICANCER, Canadian Urologic Oncology Group, Latin American Cooperative Oncology Group, Cancer Trials Ireland
Prostate Cancer
02/24
12/28
NCT02375204: Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors

Active, not recruiting
3
420
Europe, US, RoW
paclitaxel, Taxol, ifosfamide, Ifex®, IFOS, cisplatin, CDDP, pegylated G-CSF, G-CSF, carboplatin, Paraplatin®, CBDCA, etoposide phosphate, VePesid®, Toposar®, VP16, stem cell reinfusion
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), European Organisation for Research and Treatment of Cancer - EORTC, Movember Foundation, Institute of Cancer Research (ICR), United Kingdom, Cancer Research UK, UNICANCER, Irish Group CTI
Germ Cell Tumor, Teratoma, Choriocarcinoma, Germinoma, Mixed Germ Cell Tumor, Yolk Sac Tumor, Childhood Teratoma, Malignant Germ Cell Neoplasm, Extragonadal Seminoma, Non-seminomatous Germ Cell Tumor, Seminoma
06/31
06/31
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
NCT02478502 / 2012-004418-32: Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer

Terminated
2
14
Europe
cabazitaxel, Jevtana
University Hospital, Akershus, Sanofi
Testicular Cancer
12/22
12/22
NCT02303015: Toxicity Attributed to Genetic Polymorphisms in Testicular Germ Cell Tumor Survivors

Completed
N/A
430
Europe
Rigshospitalet, Denmark
Germ Cell Cancer
03/23
06/23
Pappot, Helle
TOMBOLA, NCT04138628: Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy

Recruiting
2
282
Europe
Atezolizumab
Jørgen Bjerggaard Jensen, Aarhus University Hospital, Herlev Hospital, Rigshospitalet, Denmark, Odense University Hospital, Aalborg University Hospital
Bladder Cancer, Bladder Cancer, Metastatic
08/24
11/29
NCT06480110 / 2019-004259-35: Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer

Recruiting
1/2
30
Europe
Docetaxel + Ebastine, Kestine (Ebastine), Docetaxel
Rigshospitalet, Denmark, Danish Cancer Society
Metastatic Castration-resistant Prostate Cancer
12/26
12/27
NCT05947903: Validation of the European Oncology Quality of Life Toolkit

Not yet recruiting
N/A
4000
Europe, RoW
Administration of the EUonQoL-Kit - Active Treatment questionnaire, Administration of the EUonQoL-Kit - Survivors questionnaire, Administration of the EUonQoL-Kit - Palliative Care questionnaire
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Gustave Roussy, Cancer Campus, Grand Paris, DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG (German Cancer Research Center), Oslo universitetssykehus HF, The Netherlands Cancer Institute, Hospital del Mar Research Institute, Istituto Europeo di Oncologia, European Organisation for Research and Treatment of Cancer - EORTC, UNICANCER, EAPC, Institut Curie, EUROPEAN CANCER ORGANISATION, DIGICORE/IFO, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Alleanza Contro il Cancro, Istituti Fisioterapici Ospitalieri, STICHTING NEDERLANDS INSTITUUT VOOR ONDERZOEK VAN DE GEZONDHEIDSZORG, University of Milan, SporeData OÜ, ORGANISATION OF EUROPEAN CANCER INSTITUTES, FEDERAZIONE ITALIANA DELLE ASSOCIAZIONI DI VOLONTARIATO IN ONCOLOGIA, Medical University Innsbruck, SDRUZHENIE ASOTSIATSIA NA PATSIENTITE SONKOLOGICHNI ZABOLYAVANIA I PRIYATELI, FEDERATIA ASOCIATIILOR BOLNAVILOR DE CANCER, University of Leeds, The Leeds Teaching Hospitals NHS Trust, Region Hovedstaden (Bispebjerg Hospital & Rigshospitalet)
Cancer, Survivorship, Palliative Care
10/24
10/24
MyBrain, NCT05840575: Investigating Cognitive Impairment in Young Patients With Cancer Prospectively

Recruiting
N/A
100
Europe
Rigshospitalet, Denmark
Chemotherapy-Related Cognitive Impairment, Chemotherapeutic Toxicity, Chemo-brain, Cancer, Childhood Cancer, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Testicular Cancer, Sarcoma, Leukemia
03/27
03/27
iBLAD-app, NCT05710159: The iBlad App - a National, Exploratory Study on a Multimodality Smartphone App for Bladder Cancer Patients

Recruiting
N/A
100
Europe
iBLAD Application to monitor symptoms and quality of life by the use of pateint-reported outcomes
Odense University Hospital, Rigshospitalet, Denmark, Danish Cancer Society
Bladder Cancer
06/24
12/24
Rohrberg, Kristoffer S
eNRGy, NCT02912949 / 2014-003277-42: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

Active, not recruiting
2
250
Europe, Canada, Japan, US, RoW
zenocutuzumab (MCLA-128), bispecific, MCLA-128
Merus N.V.
Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
12/26
12/26
ProTarget, NCT04341181: - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling

Recruiting
2
300
Europe
Alectinib, Alecensa, Atezolizumab, Tecentriq, Avelumab, Bavencio, Axitinib, Inlyta, Erlotinib, Tarceva, Vemurafenib plus Cobimetinib (combination), Zelboraf plus Cotellic (combination), Trastuzumab plus Pertuzumab (combination), Herceptin plus Perjeta (combination), Trastuzumab emtansine, Kadcyla, Vismodegib, Erivedge, Niraparib, Zejula
Ulrik Lassen, Roche Pharma AG, Pfizer, GlaxoSmithKline
Cancer, Tumors, Neoplasms, Neoplasia
04/24
04/25
KEYNOTE F82, NCT06205706: BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors

Hourglass Sep 2024 - Sep 2024 : Data from Part A of P1 portion of the trial studying BI-1910 as single agent for adv solid tumors
Recruiting
1/2
104
Europe, US
BI-1910, Pembrolizumab
BioInvent International AB, Merck Sharp & Dohme LLC
Solid Tumors, Non Small Cell Lung Cancer, Hepatocellular Carcinoma
07/27
11/28
LIBRETTO-001, NCT03157128 / 2017-000800-59: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

Hourglass Jan 2022 - Dec 2022 : Submission for lung cancer
Hourglass Apr 2022 - Dec 2022 : Approval in China for RET+NSCLC, medullary thyroid cancer and thyroid cancer
Checkmark From LIBRETTO-001 trial in RET fusion-positive NSCLC
Aug 2020 - Aug 2020: From LIBRETTO-001 trial in RET fusion-positive NSCLC
Checkmark Granted for advanced RET fusion+ve 2L thyroid cancer [LIBRETTO-001]
More
Active, not recruiting
1/2
856
Europe, Canada, Japan, US, RoW
LOXO-292, Selpercatinib, LY3527723
Loxo Oncology, Inc., Eli Lilly and Company
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
02/25
02/26
TEMPLE, NCT05276284: Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy

Recruiting
1/2
39
Europe
Atezolizumab, 6-mercaptopurine, 6-thioguanine
Kristoffer Rohrberg
Solid Tumor, Adult, Metastatic Cancer
08/24
08/25
Keynote-D20, NCT04752826 / 2020-002090-10: BI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies

Recruiting
1/2
176
Europe, US, RoW
BI-1808, Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection
BioInvent International AB, Merck Sharp & Dohme LLC
Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma, Melanoma
12/26
01/28
DF1001-001, NCT04143711 / 2019-004706-10: Study of DF1001 in Patients With Advanced Solid Tumors

Recruiting
1/2
378
Europe, US
DF1001, Nivolumab, Nab paclitaxel, Sacituzumab Govitecan-hziy
Dragonfly Therapeutics, Dragonfly Therapeutics, Inc.
Solid Tumor, Adult
10/26
12/26
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors
Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
NCT04855435: Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours

Recruiting
1
69
Europe
MBS8(1V270)
MonTa Biosciences ApS, Allucent
Advanced Solid Tumor
04/24
04/24
NCT04901806 / 2021-001029-32: Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

Terminated
1
29
Europe, US, RoW
PBI-200
Pyramid Biosciences, Pyramid Biosciences, Inc., Pyramid Biosciences
Solid Tumor, Adult, Brain Tumor, Primary, Desmoplastic Small Round Cell Tumor
07/23
07/23
Buchwald, Christian von
TORNADO, NCT05942222: A Randomized, Real-world Head-to-head Study of Dupilumab Versus Mepolizumab in Danish CRSwNP Patients

Recruiting
4
220
Europe
dupilumab, Dupixent, mepolizumab, Nucala
Rigshospitalet, Denmark
Chronic Rhinosinusitis With Nasal Polyps, Asthma; Eosinophilic, Eosinophilia
02/26
03/26
MESRIX-III, NCT04776538 / 2018-000348-24: Safety and Efficacy of Mesenchymal Stem Cell for Radiation-induced Hyposalivation and Xerostomia in Previous Head and Neck Cancer Patients

Active, not recruiting
2
120
Europe
Stem cells, Placebo
Rigshospitalet, Denmark, Cardiology Stem Cell Centre, The Heart Centre, Rigshospitalet, The Cell Therapy Facility, The Blood bank, Dept. of Clinical Immunology, 2034, Rigshospitalet, Denmark, Department of Oncology, 3994, Rigshospitalet, Denmark, Department of Oncology Herlev Hospital, Denmark, Department of Dentistry and Oral Health, Aarhus, Denmark
Xerostomia Following Radiotherapy
03/24
03/24
NCT03418909: Functional Outcome After Treatment for Oropharyngeal Squamous Cell Carcinoma

Active, not recruiting
N/A
44
Europe
Primary Trans Oral Robotic Surgery (TORS), Radio(chemo)therapy
Rigshospitalet, Denmark
Oropharynx Cancer, Pain, Swallowing Disorder, Quality of Life, Saliva Altered, Human Papilloma Virus
12/21
06/24
NCT04670172: Real-Life Chronic Rhinosinusitis Outcome Registry

Recruiting
N/A
4550
Europe
Change Accelerator in Respiratory Care
Chronic Rhinosinusitis (Diagnosis)
06/24
12/24
EPIC-iENE DATA, NCT05936502: Ascertaining the Radiologic Prognostic Importance of Extranodal Extension on Imaging (iENE) in Head and Neck Cancer

Completed
N/A
3500
Europe, US, RoW
Extranodal extension
Head and Neck Cancer International Group
Head and Neck Squamous Cell Carcinoma, Extranodal Extension, Human Papilloma Virus Related Carcinoma
08/23
09/23
NCT04193332: Near Infrared (NIR) Autofluorescence Image-guided Thyroid Surgery

Recruiting
N/A
214
Europe
NIR optical imaging camera
Rigshospitalet, Denmark, Cluster for molecular imaging, Denmark, Dept of Otorhinolaryngology and Maxillofacial Surgery, Zealand University Hospital, Denmark
Hypoparathyroidism Postprocedural, Hypocalcemia, Surgery--Complications
10/23
12/23
NCT06592716: Can Recurrence of Cancer in the Oropharynx Be Detected by Blood Samples?

Recruiting
N/A
200
Europe
Liquid biopsy
Rigshospitalet, Denmark, Copenhagen University Hospital, Denmark, Department of Otorhinolaryngology, Head and Neck Surgery and Audiology
Oropharyngeal Squamous Cell Carcinoma (SCC), Oropharynx Cancer, Oropharynx Cancer, Metastatic, Oropharynx Cancer, Recurrent, Oropharyngeal Carcinoma
12/28
12/28
NCT03942380: Cell-free Tumor DNA in Head and Neck Cancer Patients

Recruiting
N/A
500
Europe
Liquid biopsy
Christian von Buchwald, Copenhagen University Hospital, Denmark, Department of Otorhinolaryngology, Head and Neck Surgery and Audiology
Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer, Oropharynx Neoplasm, Oropharynx Carcinoma, Oral Cavity Cancer, Oral Cancer, Oral Neoplasm, Larynx Cancer, Larynx Carcinoma, Larynx Neoplasm, Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharynx Neoplasm, Hypopharynx Cancer, Hypopharynx Neoplasm, Hypopharynx Carcinoma, Sinonasal Carcinoma, Thyroid Carcinoma, Thyroid Cancer, Thyroid Neoplasms, Salivary Gland Cancer, Salivary Gland Neoplasms, Salivary Gland Carcinoma, Sinonasal Cancer, Sinonasal Neoplasm
02/25
02/25
QoLATI, NCT04124198: Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma

Recruiting
N/A
138
Europe
Intensity-Modulated Radiation Therapy (IMRT), Cisplatin, Nimorazole., Transoral Robotic Surgery (TORS) with neck dissection
Christian von Buchwald, Naestved Hospital, Herlev Hospital, Aarhus University Hospital, Odense University Hospital
Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma, Carcinoma, Squamous Cell, Carcinoma, Oropharyngeal Neoplasms, Neoplasms, Squamous Cell, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Pharyngeal Neoplasms Malignant and Unspecified, Otorhinolaryngologic Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, Otorhinolaryngologic Diseases, Pharyngeal Diseases, Papillomavirus Infections, Virus Diseases, DNA Virus Infections, Tumor Virus Infections, Quality of Life
12/25
01/29
Kiær, Eva K
NCT03963648: NO Measurements in Screening for Asthma and OSA, in Patients With CRSwNP

Recruiting
N/A
30
Europe
Fractioned Exhaled Nitrogen Oxide measurements
Christian von Buchwald, Bispebjerg Hospital
Chronic Rhinosinusitis (Diagnosis), Nasal Polyps, Asthma, Obstructive Sleep Apnea, Airway Disease, Inflammatory Disease, Concomitant Disease
06/22
06/22
Fosbol, Emil L
ASTERIx, NCT05061355: Antibiotics Vs Antibiotics and Surgical ThERapy for Infective Endocarditis

Recruiting
N/A
496
Europe
Heart valve surgery
Emil Loldrup Fosbol, Herlev and Gentofte Hospital, Bispebjerg Hospital, Amager Hospital, Nordsjaellands Hospital, Copenhagen University Hospital, Hvidovre
Endocarditis Infective
06/26
06/26
Fosbøl, Emil
EMPAVR, NCT06171802: EMPagliflozin After Aortic Valve Replacement

Recruiting
4
205
Europe
Empagliflozin, Jardiance, Placebo
Rigshospitalet, Denmark
Aortic Valve Stenosis
08/25
01/26
CIEDOUT, NCT06323668: Cardiac Implantable Electronic Device RemOval Versus Full CoUrse Medical Treatment

Recruiting
N/A
180
Europe
Cardiac implantable electronic device extraction
Rigshospitalet, Denmark
Cardiac Implantable Electronic Device Infection
06/28
01/38
NCT05432427: 64Cu-DOTATATE PET-CT-skanning and Infective Endocarditis.

Completed
N/A
69
Europe
64Cu-DOTATATE and 18F-FDG
Emil Loldrup Fosbol
Endocarditis, Endocarditis;Chronic, Endocarditis Acute
09/23
09/23
TACTICS, NCT06638268: Transcatheter AortiC Valve Implantation in AorTic StenosIs CardiogenIc Shock

Not yet recruiting
N/A
30
Europe
Acute TAVI, Stabilization and subacute TAVI
Rigshospitalet, Denmark, Odense University Hospital
Aortic Stenosis, Cardiogenic Shock
07/27
07/27
CIEDLESS, NCT05958290: Cardiac Implantable Electronic Device Lifelong Antibiotic thErapy vs Stop and See

Recruiting
N/A
90
Europe
Discontinuation of antibiotics
Rigshospitalet, Denmark
Cardiac Implantable Electronic Device Infection
11/25
11/25
ASTERIx, NCT05061355: Antibiotics Vs Antibiotics and Surgical ThERapy for Infective Endocarditis

Recruiting
N/A
496
Europe
Heart valve surgery
Emil Loldrup Fosbol, Herlev and Gentofte Hospital, Bispebjerg Hospital, Amager Hospital, Nordsjaellands Hospital, Copenhagen University Hospital, Hvidovre
Endocarditis Infective
06/26
06/26
Spanggaard, Iben
TEMPLE, NCT05276284: Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy

Recruiting
1/2
39
Europe
Atezolizumab, 6-mercaptopurine, 6-thioguanine
Kristoffer Rohrberg
Solid Tumor, Adult, Metastatic Cancer
08/24
08/25
CDR404-001, NCT06402201: First in Human Study of CDR404 in HLA-A*02:01 Participants with MAGE-A4 Expressing Solid Tumors

Recruiting
1
42
Europe, US
CDR404
CDR-Life AG
Select Advanced Solid Tumors
06/26
12/27
Højgaard, Martin
TEMPLE, NCT05276284: Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy

Recruiting
1/2
39
Europe
Atezolizumab, 6-mercaptopurine, 6-thioguanine
Kristoffer Rohrberg
Solid Tumor, Adult, Metastatic Cancer
08/24
08/25

Download Options